ERBB2 and neoplasm: Most CAR-NK cell therapies, including those targeting hematologic targets (e.g., CD19, CD20, and CD138) (95–97) and solid tumors (e.g., HER2, GD2, PSCA, and EGFRvIII), have been evaluated for efficacy in tumor xenograft (PDX) models (98–100).